NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Around 10-20% of people who contract Lyme disease, the most common tickborne disease in the U.S., develop persistent, often debilitating symptoms such as chronic pain, fatigue, and cognitive dysfunction. Lyme infection-associated chronic illnesses (IACI) share symptoms common to other IACI such as Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome. Despite the chronic impact on the quality of life for many people, there are currently no validated interventions to treat Lyme IACI.
In response to this unmet need, the Steven & Alexandra Cohen Foundation asked the National Academies to convene a committee of experts to assess the evidence for disease mechanisms, diagnoses, and treatments of Lyme IACI and illuminate a pathway for the development of new treatments. The resulting report, Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses, makes recommendations around developing treatments that improve function and quality of life based on currently available evidence, while continuing research to identify root causes and mechanisms of the disease.
Contents
- The National Academies of SCIENCES • ENGINEERING • MEDICINE
- COMMITTEE ON THE EVIDENCE BASE FOR LYME INFECTION-ASSOCIATED CHRONIC ILLNESSES TREATMENT
- Reviewers
- Acknowledgments
- Preface
- Acronyms and Abbreviations
- Glossary
- Summary
- 1. Introduction
- 2. State of the Evidence
- 3. Building on Research from Other Infection-Associated Chronic Illnesses
- 4. Innovative Approaches to Accelerating Lyme IACI Research
- 5. Recommendations
- Appendix A. Committee Meeting Agendas
- Appendix B. Committee Member and Staff Biographies
- Appendix C. Methodology of Literature Review
Suggested citation:
National Academies of Sciences, Engineering, and Medicine. 2025. Charting a path toward new treatments for Lyme infection-associated chronic illnesses. Washington, DC: National Academies Press. https://doi.org/10.17226/28578.
Digital Object Identifier: https://doi.org/10.17226/28578
Library of Congress Control Number: 2025938379
This publication is available from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242; http://www.nap.edu.
The manufacturer's authorized representative in the European Union for product safety is Authorised Rep Compliance Ltd., Ground Floor, 71 Lower Baggot Street, Dublin D02 P593 Ireland; www.arccompliance.com.
Printed in the United States of America.
Created: May 8, 2025; Last Update: June 26, 2025.
- Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illn...Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses
Your browsing activity is empty.
Activity recording is turned off.
See more...